Cymerin (ranimustine) / Mitsubishi Tanabe - LARVOL DELTA

Treatment and Outcome of ATL Diagnosed in 2021 to 2023 By the Kagoshima ATL Registry (ASH 2024) - "Among them, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), VCAP-AMP-VECP (VCAP : vincristine, cyclophosphamide, doxorubicin, and prednisolone, AMP : doxorubicin, ranimustine, and prednisolone, and VECP : vindesine, etoposide, carboplatin, and prednisolone), any chemotherapy by cytotoxic agents combined with mogamulizumab (Moga+CTx), and CHP therapy combined with brentuximab vedotin (BV-CHP) were performed in 30.0 %, 28.3 %, 28.3 %, and 13.4% of patients, respectively. BV or Moga with or without CTx were most frequently used in the second-line treatment (n=81). This registration is expected to provide real-world data of ATL by regional registry in one of the world's most endemic area in HTLV-1 under the circumstances of the decreasing of HTLV-1 infected individuals in younger people and recent Introduction of novel therapeutic agents including tucidinostat and valemetostat in Japan."

Adult T-Cell Leukemia-Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

The Role of High-Dose Regimens Followed By Autologous Stem Cell Transplantation for Salvage Chemotherapy-Sensitive DLBCL Patients (ASH 2023) - "Introduction: It has been reported that lisocabtagene maraleucel improved event-free survival and complete response rate compared with standard care as second -line therapy for early relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) patients(pts)...Further, we have also used ranimustine (MCNU) based MEAM regimen due to not availability for carmustine in Japan...AECC regimen consists of nimustine 200mg/m 2 on day -7 to day -6, etoposide (ETP) 30mg/kg on day -5 to day -4, cyclophosphamide 60mg/kg on day -3 to day -2, carboplatin 700mg/m 2 on day -3 to day -2. MEAM regimen consists of MCNU 300 mg/m 2 on day -7, ETP 200 mg/m 2 on day -6 to day -3, cytarabine 200 mg/m 2 q12 hrs on day -6 to day -3, and melphalan 140 mg/m 2 on day -2...However, AECC was associated with a higher incidence of cardiac toxicity and TRM within 100 days. It was suggested that auto-SCT with AECC may be a treatment option when CAR T-cell therapy was not available."

Clinical • B Cell Lymphoma • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • Hepatology • Infectious Disease • Liver Failure • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Transplantation

Transplant-Associated Thrombotic Microangiopathy After Autologous Hematopoietic Stem Cell Transplantation Treated With Eculizumab. (PubMed, Cureus) - "A 66-year-old woman in complete remission after the second relapse of follicular lymphoma received autologous HSCT following the MEAM regimen (ranimustine [MCNU], etoposide, cytarabine [Ara-C], and melphalan). Even with serious complications such as PH and RHF, TA-TMA after autologous HSCT may improve with early diagnosis and prompt initiation of complement-targeting agents, such as eculizumab. These findings suggest that complement inhibition may play a critical therapeutic role even in patients with cardiopulmonary complications and raise the possibility that the prognosis of TA-TMA after autologous HSCT may be more favorable than previously reported in allogeneic HSCT, with a lower mortality rate."

Journal • Bone Marrow Transplantation • Cardiovascular • Congestive Heart Failure • Follicular Lymphoma • Graft versus Host Disease • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypertension • Immunology • Lymphoma • Oncology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia • Transplantation • CD46

Discordant lymphoma characterized by the coexistence of diffuse large B-cell lymphoma in the brain and mantle cell lymphoma in the colon, rectum, and bone marrow. (PubMed, Brain Tumor Pathol) - "After five cycles of R-MPV (rituximab, methotrexate, procarbazine, vincristine) therapy and three cycles of R-ESHAP (rituximab, etoposide, cytarabine, cisplatin, methylprednisolone) therapy, the patient received autologous hematopoietic stem cell transplantation using R-MEAM (rituximab, ranimustine, etoposide, cytarabine, melphalan) regimen after bridging therapy with ibrutinib. He did not relapse within 3 years of transplantation. To the best of our knowledge, this is the first case report of DLBCL and MCL coexistence."

Journal • B Cell Lymphoma • Bone Marrow Transplantation • CNS Lymphoma • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • IGH

Evaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study. (PubMed, J Clin Exp Hematop) - "Furthermore, a ranimustine, cytarabine, etoposide, and cyclophosphamide (MCVAC) conditioning regimen has been effective in diffuse large B-cell lymphoma. Two patients died because of treatment-related factors, and one patient died because of disease progression. Based on our findings, recognizing the risk factors for adverse events (AEs) associated with this treatment, MCVAC may be a valid treatment option for the management of RRcHL."

Journal • Retrospective data • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

MCVAC Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed and Refractory Hodgkin Lymphoma: A Single‑Institution Retrospective Study (SOHO 2023) - "The MCVAC conditioning regimen (ranimustine 250 mg/m2 on day −9 and 200 mg/m2 on day −4, cytarabine 2.0 g/m2 twice daily on days −8 to −5, etoposide 200 mg/m2 twice daily on days −8 to −5, and cyclophosphamide 50 mg/kg on days −3 and −2) administered before ASCT has been shown to be effective for the treatment of diffuse large B-cell lymphoma. MCVAC conditioning regimen before ASCT for relapsed or refractory Hodgkin lymphoma was useful and tolerated by patients. Based on our findings, we suggest that MCVAC could be a valid treatment option for the management of relapsed or refractory Hodgkin lymphoma."

Retrospective data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Antineoplastic Drug Use Resulting in Cardiac Failure: Disproportionality Analysis of FDA Adverse Drug Event Reporting System (FAERS) Database Using Exploratory Big Data Analysis (ISPOR 2023) - "The top 4 highest positive signal (HPS) for drugs were Streptozocin ROR 47.674 (28.090-80.911), Ranimustine ROR 31.049 (17.521-55.022), Aclarubicin ROR 12.654 (5.587-28.662) and Entrectinib ROR 10.043(6.277-16.070) . Cyclophosphamide had the highest case reports (N=765, 9.35%) followed by doxorubicin (N=706, 8.62%)... Prominent number CF cases were reported with antineoplastic drugs. Data was presented with and without stratification by age, gender and outcome of the adverse drug reaction. Our EDA uncovered Entrectinib a newly tyrosine kinase inhibitor approved by FDA in 2019 and there is no biomedical literature available which defines its causality for CF."

Adverse events • Cardiovascular • Congestive Heart Failure • Heart Failure • Oncology • Pediatrics

Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study. (PubMed, Asia Pac J Clin Oncol) - "The safety and efficacy of high-dose Ara-C MEAM therapy were demonstrated, but the expected therapeutic effect on central nervous system lesions could not be fully evaluated owing to the small number of cases."

Journal • Retrospective data • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation